This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Are You Looking for a Top Momentum Pick? Why Bristol-Myers Squibb (BMY) is a Great Choice
by Zacks Equity Research
Does Bristol-Myers Squibb (BMY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BMY or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
How Trading Your Own Retirement Can Fleece Your Financial Future - January 03, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
Top Ranked Momentum Stocks to Buy for January 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 2nd.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $64.19, marking a +0.72% move from the previous day.
Easy Investing Secrets to an Early Retirement - December 31, 2019
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China
by Zacks Equity Research
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
Why Bristol-Myers (BMY) Stock Might be a Great Pick
by Zacks Equity Research
Bristol-Myers (BMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for EUSA
Top Ranked Momentum Stocks to Buy for December 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th
Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down
by Zacks Equity Research
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
Top Ranked Momentum Stocks to Buy for December 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 26th.
How Trading Your Own Retirement Can Fleece Your Financial Future - December 24, 2019
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Here is Why Growth Investors Should Buy Bristol-Myers (BMY) Now
by Zacks Equity Research
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market.
Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication
by Zacks Equity Research
The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
Want To Retire Early? Learn the Intelligent Investing Secret - December 23, 2019
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
2019 Was a Tough Year but These 5 Stocks May Rebound in 2020
by Nilanjan Choudhury
There are chances that some of the underperforming stocks of 2019 might rebound in 2020 given the favorable factors and their fundamental strength.
Zacks.com featured highlights include: Synaptics, Target, Medtronic Public, Bristol-Myers Squibb and Integer
by Zacks Equity Research
Zacks.com featured highlights include: Synaptics, Target, Medtronic Public, Bristol-Myers Squibb and Integer
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 19, 2019
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Buy These 5 Stocks With Upgraded Broker Ratings for 2020
by Swayta Shah
When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.
20 Stocks From Top 20 Industries to Double Your Money in 2020
by Sweta Killa
It's time to think big and set an investment goal for 2020 that could double your money. The key to accomplish this task is to look for top-ranked stocks in top-ranked industries.